Intravenous AAV9-ATP7A plus subcutaneous copper histidinate optimizes outcomes in a lethal Menkes disease mouse model

Journal:

Science Advances

Published:

2025-08-29

DOI:

10.1126/sciadv.adw5612

Affiliations:

3

Authors:

7

Go to article

Institutions	Authors	Share
OSU Department of Pediatrics (Nationwide Children's Hospital), United States of America (USA)	4.000000	0.57
NIH National Institute of Neurological Disorders and Stroke (NINDS), United States of America (USA)	2.000000	0.29
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.14

Interested in Clinical Sciences?